Warm Autoimmune Hemolytic Anemia Market in the 7MM reached approximately USD 600 million in 2025 and is anticipated to expand steadily through 2036, according to DelveInsight

DelveInsight's report titled "Warm Autoimmune Hemolytic Anemia Market Insights, Epidemiology, and Market Forecast - 2036" provides a comprehensive analysis of the disease, including historical and projected epidemiological data, along with evolving market trends across the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan.

Access the complete report to gain insights into market dynamics, pipeline developments, and upcoming therapies: https://www.delveinsight.com/sample-request/warm-autoimmune-hemolytic-anemia-waiha-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key Highlights from the Warm Autoimmune Hemolytic Anemia Market Report
• On January 27, 2026, Incyte Corporation initiated a clinical study to assess the safety and effectiveness of tafasitamab in adult patients with primary autoimmune hematologic conditions.
• On January 16, 2026, Janssen Research & Development LLC launched a study featuring a 24-week double-blind placebo-controlled phase, followed by a 144-week open-label extension and an 8-week follow-up period. Participants will receive either placebo or varying doses of nipocalimab during both phases.
• On January 15, 2026, Novartis Pharmaceuticals conducted a study evaluating the safety and efficacy of ianalumab versus placebo in patients with warm autoimmune hemolytic anemia who had failed prior treatments. The primary goal is to confirm sustained hemoglobin response. The study includes structured treatment, monitoring, and follow-up phases extending up to 39 months.
• Among the 7MM regions, the United States reported the highest number of prevalent autoimmune hemolytic anemia cases in 2023, with approximately 57,000 patients, a number expected to rise during the forecast period.
• Gender-based analysis indicates that females accounted for nearly 60% of wAIHA cases in 2023 in the US, with projections suggesting further growth by 2036.
• Within EU4 and the UK, Germany recorded the highest prevalence, whereas Spain reported the lowest number of cases in 2023.
• In Japan, individuals aged 65 years and above represented over 64% of total cases in 2023, indicating a higher disease burden in the elderly population.
• Major companies involved in the wAIHA market include Rigel Pharmaceuticals, Apellis Pharmaceuticals, Johnson & Johnson, Sanofi, Incyte Corporation, Annexon, and others.
• Prominent therapies under development include INCA000585, Povetacicept, Ianalumab, APL-2, Fostamatinib Disodium, ANX005, Fostamatinib 150 mg BID, Rilzabrutinib, HMPL-523 (300 mg PO QD), among others.

Gain deeper strategic insights and competitive intelligence into the market:
https://www.delveinsight.com/sample-request/warm-autoimmune-hemolytic-anemia-waiha-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Epidemiological Segmentation of Warm Autoimmune Hemolytic Anemia in the 7MM
• Total diagnosed prevalence of autoimmune hemolytic anemia
• Overall prevalence of wAIHA
• Distribution based on disease type
• Gender-based prevalence
• Age-specific prevalence

Download the report to explore key epidemiological drivers: https://www.delveinsight.com/sample-request/warm-autoimmune-hemolytic-anemia-waiha-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Warm Autoimmune Hemolytic Anemia Treatment Landscape
Management of wAIHA primarily focuses on controlling the autoimmune response, alleviating symptoms, and preventing complications. Corticosteroids such as prednisone are commonly used as first-line therapy due to their immunosuppressive properties.
For patients who do not respond well or cannot tolerate steroids, alternative immunosuppressants like azathioprine, rituximab, mycophenolate mofetil, or cyclophosphamide may be utilized. Intravenous immunoglobulin (IVIG) therapy can provide rapid symptom relief in severe cases.
Splenectomy may be considered in refractory patients, although it carries risks and is generally reserved for select cases. Supportive treatments such as blood transfusions and folic acid supplementation are often required. Long-term care involves regular monitoring, treatment adjustments, and multidisciplinary collaboration to optimize patient outcomes.

Emerging Warm Autoimmune Hemolytic Anemia Therapies
• Obexelimab (ZB012): Zenas BioPharma
Obexelimab is a first-in-class bifunctional antibody targeting CD19-positive B cells. It works by mimicking natural immune complexes and suppressing B-cell activity without depleting them. Early studies have demonstrated promising efficacy across autoimmune diseases. It is currently in Phase III (SApHiAre trial).
• Nipocalimab (M281): Johnson & Johnson Innovative Medicine
Nipocalimab is a monoclonal antibody targeting the FcRn receptor, reducing IgG-mediated autoimmune activity. It has received Fast Track Designation (FTD) and Orphan Drug Designation (ODD) and is currently being evaluated in Phase II/III clinical trials.

Explore future treatment innovations and forecasts:
https://www.delveinsight.com/sample-request/warm-autoimmune-hemolytic-anemia-waiha-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key Companies in the Warm Autoimmune Hemolytic Anemia Market
Rigel Pharmaceuticals, Apellis Pharmaceuticals, Johnson & Johnson, Sanofi, Incyte Corporation, Annexon, and others.
Warm Autoimmune Hemolytic Anemia Market Outlook
Corticosteroids remain the cornerstone of wAIHA treatment. In cases where they fail, splenectomy may be considered. Rituximab has emerged as an effective option for refractory disease and is increasingly being combined with prednisone as a first-line approach.
The introduction of rituximab has shifted traditional treatment paradigms, pushing older immunosuppressive therapies such as azathioprine and cyclophosphamide to later lines of treatment. Advances in targeted therapies are expected to further transform the treatment landscape.

Access full market insights, including emerging drugs and competitive dynamics:
https://www.delveinsight.com/sample-request/warm-autoimmune-hemolytic-anemia-waiha-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Scope of the Warm Autoimmune Hemolytic Anemia Market Report
• Coverage: 7MM
• Study Period: 2020-2036
• Key Companies: Rigel Pharmaceuticals, Apellis Pharmaceuticals, Johnson & Johnson, Sanofi, Incyte Corporation, Annexon, and others
• Key Therapies: Riliprubart, Batoclimab, Efgartigimod PH20 SC, SAR445088 (IV), and others
• Therapeutic Assessment: Current and emerging treatment options
• Market Dynamics: Drivers and barriers influencing market growth
• Competitive Intelligence: SWOT, PESTLE, Porter's Five Forces, BCG Matrix, and market entry strategies
• Unmet Needs, KOL insights, analyst perspectives, and reimbursement landscape

Table of Contents
1. Key Insights
2. Report Introduction
3. Market Overview Snapshot
4. Methodology for Epidemiology and Forecasting
5. Executive Summary
6. Key Developments
7. Disease Background and Overview
8. Treatment and Management
9. Epidemiology and Patient Pool
10. Patient Journey
11. Marketed Therapies
12. Emerging Therapies
13. 7MM Market Analysis
14. KOL Perspectives
15. SWOT Analysis
16. Unmet Needs
17. Reimbursement Landscape
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.